Clinicopathologic and survival study of patients with Ewing family of tumors: A retrospective-analytical study

Shokouh Taghipour Zahir, Maryam Mirzaei, Seyed Mohammadreza Mortazavizadeh, Farzan SafiDahaj, Koorosh Rahmani, Hamidreza Mohammadi, Sajad Sadeghinejad-Alamabadi


With significant mortality among malignancies, Ewing's family of tumors stands out as one of the most malignant cancers in young patients. This study aims to investigate clinicopathological characteristics and the impact of demographic and treatment types on survival. This retrospective-analytical study was conducted using the census method at Shahid Sadoughi Hospital in Yazd. The study included all patients with Ewing's family of tumors referred to these hospitals from 2011 to 2018. Demographic and disease characteristics were collected from the registry and analyzed using SPSS v.17. Fifty patients were enrolled in the study, with a mean age of 19.14±15.92 years. The lower extremity (30%) and abdominopelvic (24%) were the most common sites of the primary tumor, respectively. The mean tumor size was 5.76 ± 3.92 cm, and metastasis occurred in 16% of patients. Among them, 42% underwent combination therapy (chemotherapy/radiotherapy/ surgery), and 40% underwent chemotherapy + surgery. The disease relapsed in 62% of patients, and the most common site of recurrence was the chest wall (38%). The mean overall survival was 87.82 ± 11.54 months. Tumor location was associated with overall survival. Gender, age group, tumor size, and treatment type did not affect overall survival (P> 0.05). The mean survival until disease recurrence was 57.74 ± 7.74 months. It was concluded that recurrence is common in Ewing sarcomas, with the chest wall being the most common site of recurrence. Overall survival is linked to tumor location.


Ewing sarcoma, head and neck neoplasm, survival, primitive neuroectodermal tumor

Full Text:



Jagodzińska-Mucha P, Raciborska A, Koseła-Paterczyk H, et al. Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience. J Clin Med 10:3627, 2021.

Esen SA, Acikgoz Y, Bal O, et al. A Comparison of

osseous and extraosseous Ewing sarcoma. J Coll Physicians

Surg Pak 31:27-33, 2021.

Riggi N, Stamenkovic I. The biology of Ewing sarcoma. Cancer Lett 254:1-10, 2007.

Abboud A, Masrouha K, Saliba M, et al. Extraskeletal Ewing sarcoma: Diagnosis, management and prognosis (Review). Oncol Lett 21:354, 2021.

Woo CG, Lee B, Song JS, et al. Clinicopathologic features of the non-CNS primary Ewing sarcoma family of tumors in the head and neck region. Appl Immunohistochem Mol Morphol 26:632-639, 2018.

Machado I, Navarro S, López-Guerrero JA, et al. Neuroendocrine differentiation in a large series of genetically-confirmed Ewing's sarcoma family tumor: Does it provide any diagnostic or prognostic information? Pathol Res Pract 219:153362, 2021.

Umeda K, Miyamura T, Yamada K, et al. Clinical outcome of patients with recurrent or refractory localized Ewing's sarcoma family of tumors: A retrospective report from the Japan Ewing Sarcoma Study Group. Cancer Rep (Hoboken) 4:e1329, 2021.

Singh AD, Husson M, Shields CL, et al. Primitive neuroectodermal tumor of the orbit. Arch Ophthalmol 112:217-221, 1994.

Mishra MN, Sharma R, Chandavarkar V, et al. Pathogenesis of Ewing sarcoma: Existing and emerging trends. Adv Cancer Biology-Metastasis 2:100008, 2021.

Tamer C, Oksuz H, Hakverdi S, et al. Primary peripheral primitive neuroectodermal tumour of the orbit. Can J Ophthalmol 42:138-140, 2007.

Bakhshi S, Meel R, Naqvi SGH, et al. Therapy and outcome of orbital primitive neuroectodermal tumor. Pediatr Blood Cancer 52:544-547, 2009.

Jones JE, McGill T. Peripheral primitive neuroectodermal tumors of the head and neck. Arch Otolaryngol Head Neck Surg 121:1392-5, 1995.

Kim SY, Tsokos M, Helman LJ. Dilemmas associated with congenital ewing sarcoma family tumors. Pediatr Hematol Oncol J 30:4, 2008.

Stout A, editor A tumor of ulnar nerve. Proc NY Pathol Soc; 1918.

Wong D, Weatherhead R. Congenital orbital primitive neuroectodermal tumour. Clin Experiment Ophthalmol 43:845-847, 2015.

Chokthaweesak W, Annunziata CC, Alsheikh O, et al. Primitive neuroectodermal tumor of the orbit in adults: a case series. Ophthalmic Plast Reconstr Surg; 27:173-9, 2011.

Arora RS, Alston RD, Eden TO, et al. The contrasting age‐incidence patterns of bone tumours in teenagers and young adults: Implications for aetiology. Int J Cancer 131:1678-1685, 2012.

Duchman KR, Gao Y, Miller BJ. Prognostic factors for survival in patients with Ewing's sarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol 39:189-195, 2015.

Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: national cancer data base report. Clin Orthop Relat Res 459:40-47, 2007.

Esiashvili N, Goodman M, Marcus RB. Changes in

incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol 30:425-4230, 2008.

Gaspar N, Hawkins DS, Dirksen U, et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 33:3036-3046, 2015.

Marina N, Meyers PA. High-dose therapy and stem-cell rescue for Ewing's family of tumors in second remission. Am J Clin Oncol. 2005.

Rodríguez-Galindo C, Liu T, Krasin MJ, et al. Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer 110:375-384, 2007.

Stahl M, Ranft A, Paulussen M, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 57:549-553, 2011.

Verma V, Denniston KA, Lin CJ, et al. A comparison of pediatric vs. adult patients with the Ewing sarcoma family of tumors. Front Oncol 7:82, 2017.

Friedman DN, Chastain K, Chou JF, et al. Morbidity and mortality after treatment of Ewing sarcoma: A single‐institution experience. Pediatr Blood Cancer 64: e26562, 2017.

Albergo J, Gaston C, Laitinen M, et al. Ewing’s sarcoma: only patients with 100% of necrosis after chemotherapy should be classified as having a good response. Bone Joint J 98:1138-1144, 2016.

Lee JA, Kim DH, Cho J, et al. Treatment outcome of Korean patients with localized Ewing sarcoma family of tumors: a single institution experience. Jpn J Clin Oncol 41:776-782, 2011.

Lee J, Hoang BH, Ziogas A, et al. Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry. Cancer 116:1964-1973, 2010.

Koohbanani B, Han G, Reed D, et al. Ethnicity and age disparities in Ewing sarcoma outcome. Fetal Pediatr Pathol 32:246-252, 2013.

Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing’s sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 18:4-4, 2000.

Jawad MU, Cheung MC, Min ES, et al. Ewing sarcoma demonstrates racial disparities in incidence‐related and sex related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005. Cancer: Interdisciplinary International Journal of the American Cancer Society 115: 3526-3536, 2009.

Miller BJ, Gao Y, Duchman KR. Does surgery or radiation provide the best overall survival in Ewing's sarcoma? A review of the National Cancer Data Base. J Surg Oncol 116:384-390, 2017.

Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 18:3108-114, 2000.

Kharod SM, Spiguel AR, Lagmay JP, et al. Radiation treatment for Ewing sarcoma family of tumors in adult patients: a single institution’s experience over 40 years. Am J Clin Oncol 42:421-425, 2019.


  • There are currently no refbacks.